
WARF Launches Essay Series Highlighting University Innovation
The inaugural essay, authored by Kevin Conroy, Chairman and CEO of Exact Sciences, is titled "How Wisconsin Ingenuity Is Shaping the Future." Conroy's essay explores the pivotal role that Wisconsin's innovative spirit plays in driving scientific discovery and economic growth. He shares his personal experiences with WARF, emphasizing its support in transforming groundbreaking research into real-world applications.
Conroy highlights how WARF's strategic investments and collaborative efforts have been instrumental in turning lesser-known scientific discoveries into transformative technologies. For example, a variation of an enzyme discovered by Jim Dahlberg became part of the cervical cancer test developed at Third Wave Technologies and is now used in Exact Sciences' Cologuard® test, which has screened over 19 million people for colorectal cancer.
Throughout the year, WARF will publish additional essays from various thought leaders, each offering unique perspectives on the impact of university research on global challenges. These essays will be available at warf.org/WisconsinIngenuity and will underscore the importance of long-term investments in university innovation and the transformative potential of academic-industry partnerships.
About WARF
Celebrating a century of service in 2025, the Wisconsin Alumni Research Foundation (WARF) patents and licenses discoveries from UW-Madison research, manages an investment portfolio generated from licensing and investment proceeds, and provides annual grants to the University of Wisconsin-Madison and the Morgridge Institute for Research to support further scientific investigation and research. By driving collaborations among researchers, investors, industry and entrepreneurs, WARF commercializes innovations from campus through various initiatives. WARF Accelerator improves the commercialization potential of university intellectual property through industry engagement and investment in proof-of-concept milestones to validate market potential, demonstrate commercial value and de-risk technology. WARF Therapeutics partners with UW-Madison and Morgridge Institute researchers employing an industry-focused approach to improve the value propositions of drug candidates. WARF Ventures is an early-stage venture fund that invests in startups based on UW/WARF technologies. Learn more at warf.org.
Jeanan Yasiri Moe
Wisconsin Alumni Research Foundation (WARF)
+1 608-960-9892
jyasirimoe@warf.org
Visit us on social media:
LinkedIn
Bluesky
Instagram
Facebook
YouTube
X

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry, Science, Technology, World & Regional
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Submit your press release